{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:32:21Z","timestamp":1760239941464,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.hoc.2020.06.011","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T08:01:57Z","timestamp":1596614517000},"page":"971-982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Priyanka A.","family":"Pophali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gita","family":"Thanarajasingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2020.06.011_bib2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","article-title":"Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes","volume":"273","author":"Wilson","year":"1995","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.011_bib3","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1016\/S2352-3026(18)30051-6","article-title":"Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies","volume":"5","author":"Thanarajasingam","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2020.06.011_bib5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"10.1016\/j.hoc.2020.06.011_bib6","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3109\/10428194.2012.762977","article-title":"A\u00a0preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy - Lymphoma Symptom Index","volume":"54","author":"Hlubocky","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.011_bib8","first-page":"155","article-title":"EuroQol-5D (EQ-5D): an instrument for measuring quality of life","volume":"78","author":"Balestroni","year":"2012","journal-title":"Monaldi Arch Chest Dis"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.011_bib9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ejon.2013.05.006","article-title":"EORTC QLQ-C30 and FACT-Lym for the assessment of health-related quality of life of newly diagnosed lymphoma patients undergoing chemotherapy","volume":"17","author":"Georgakopoulos","year":"2013","journal-title":"Eur J Oncol Nurs"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.011_bib10","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.011_bib11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.011_bib12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00277-017-3180-x","article-title":"R-hyper-CVAD versus R-CHOP\/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience","volume":"97","author":"Widmer","year":"2018","journal-title":"Ann Hematol"},{"issue":"19","key":"10.1016\/j.hoc.2020.06.011_bib13","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"9873","key":"10.1016\/j.hoc.2020.06.011_bib14","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.011_bib15","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clml.2016.01.001","article-title":"Differences in quality of life between bendamustine-rituximab and R-CHOP\/R-CVP in patients with previously untreated advanced indolent non-Hodgkin lymphoma or mantle cell lymphoma","volume":"16","author":"Burke","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"year":"2017","series-title":"Common terminology criteria for adverse events (CTCAE) version 5.0","key":"10.1016\/j.hoc.2020.06.011_bib16"},{"issue":"17","key":"10.1016\/j.hoc.2020.06.011_bib17","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2004.03.025","article-title":"How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30","volume":"22","author":"Fromme","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.011_bib18","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1470-2045(06)70910-X","article-title":"Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study","volume":"7","author":"Basch","year":"2006","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.hoc.2020.06.011_bib19","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/jnci\/djr493","article-title":"Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events","volume":"103","author":"Basch","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.011_bib20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/sj.bmt.1700672","article-title":"Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale","volume":"19","author":"McQuellon","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.011_bib21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2019.09.007","article-title":"Evaluation of the impact of autologous hematopoietic stem cell transplantation on the quality of life of older patients with lymphoma","volume":"26","author":"Lemieux","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2020.06.011_bib22","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.bbmt.2017.12.582","article-title":"Long term quality of life in lymphoma patients after autologous hematopoietic cell transplantation","volume":"24","author":"Farooq","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"13","key":"10.1016\/j.hoc.2020.06.011_bib23","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.011_bib24","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1097\/HS9.0000000000000136","article-title":"Maintenance treatment for patients with mantle cell lymphoma: a systematic review and meta-analysis of randomized trials","volume":"2","author":"Vidal","year":"2018","journal-title":"Hemasphere"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2020.06.011_bib25","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/blood-2019-129404","article-title":"Maintenance rituximab improves outcomes in mantle cell lymphoma patients who respond to induction therapy with bendamustine\u00a0+ rituximab without autologous transplant","volume":"134","author":"Hill","year":"2019","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2020.06.011_bib26","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2016.34.15_suppl.7503","volume":"34","author":"Rummel","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.011_bib27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00277-008-0560-2","article-title":"Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial","volume":"88","author":"Witzens-Harig","year":"2009","journal-title":"Ann Hematol"},{"issue":"19","key":"10.1016\/j.hoc.2020.06.011_bib28","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.06.011_bib29","unstructured":"Basch E, Campbell A, Hudgens S, et\u00a0al. Broadening the definition of tolerability in cancer clinical trials to better measure the patient experience. 2018. Availabe at: https:\/\/www.focr.org\/sites\/default\/files\/Comparative%20Tolerability%20Whitepaper_FINAL.pdf. Accessed April 7, 2020."},{"key":"10.1016\/j.hoc.2020.06.011_bib30","doi-asserted-by":"crossref","unstructured":"Kluetz PG, Kanapuru B, Lemery S, et\u00a0al. Informing the tolerability of cancer treatments using patient-reported outcome measures: summary of an FDA and Critical Path Institute Workshop. Value in Health 2018;21(6):742-7.","DOI":"10.1016\/j.jval.2017.09.009"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.011_bib31","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1080\/10428194.2017.1326034","article-title":"Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus","volume":"58","author":"Hess","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2020.06.011_bib32","unstructured":"Rule S, Arcaini L, Jan W, et\u00a0al. Quality of life in relapsed\/refractory mantle cell lymphoma patients treated with lenalidomide vs investigator\u2019s choice: MCL-002 (SPRINT) trial. European Haematology Association. Vienna, June 11-14, 2015."},{"issue":"1","key":"10.1016\/j.hoc.2020.06.011_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2008-10-182592","article-title":"Quality of life after allogeneic hematopoietic cell transplantation","volume":"114","author":"Pidala","year":"2009","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2020.06.011_bib34","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood-2019-126064","article-title":"KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T\u00a0cell therapy, in patients (Pts) with relapsed\/refractory (R\/R) mantle cell lymphoma (MCL): results of the phase 2 ZUMA-2 study","volume":"134","author":"Michael","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2020.06.011_bib35","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1182\/blood-2019-121715","article-title":"Patient experience of chimeric antigen receptor (CAR)-T cell therapy vs. stem cell transplant: longitudinal patient reported adverse events, cognition and quality of life","volume":"134","author":"Sidana","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.011_bib36","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3109\/10428194.2012.711830","article-title":"The Functional Assessment of Cancer Therapy - general (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma","volume":"54","author":"Yost","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.011_bib37","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1182\/blood.V112.11.2376.2376","article-title":"Validation of the Functional Assessment of Cancer Therapy\u2013Lymphoma (FACT-LYM) in patients with relapsed\/refractory mantle cell lymphoma","volume":"112","author":"Carter","year":"2008","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.hoc.2020.06.011_bib38","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1200\/JCO.2008.20.0634","article-title":"Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients","volume":"27","author":"Courneya","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.011_bib39","first-page":"2153","article-title":"Association of social network and social support with health-related quality of life and fatigue in long-term survivors of Hodgkin lymphoma","volume":"21","author":"Soares","year":"2013","journal-title":"Support Care Cancer"},{"issue":"18","key":"10.1016\/j.hoc.2020.06.011_bib40","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1002\/cncr.29490","article-title":"Are lifestyle behavioral factors associated with health-related quality of life in long-term survivors of non-Hodgkin lymphoma?","volume":"121","author":"Spector","year":"2015","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.011_bib41","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.011_bib42","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/cncr.31133","article-title":"Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy","volume":"124","author":"Pearman","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2020.06.011_bib43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/EDBK_159514","article-title":"Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"35","author":"Kluetz","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.011_bib44","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2017.21903","article-title":"Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension","volume":"319","author":"Calvert","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.011_bib45","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.011_bib46","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv216","article-title":"The imperative for a new approach to toxicity analysis in oncology clinical trials","volume":"107","author":"Thanarajasingam","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.011_bib47","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(16)00038-3","article-title":"Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254","volume":"17","author":"Thanarajasingam","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.011_bib48","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/annonc\/mdr146","article-title":"Toxicity burden score: a novel approach to summarize multiple toxic effects","volume":"23","author":"Lee","year":"2012","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.011_bib49","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/annonc\/mdw218","article-title":"How to report toxicity associated with targeted therapies?","volume":"27","author":"Cabarrou","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.011_bib50","doi-asserted-by":"crossref","first-page":"e000284","DOI":"10.1136\/esmoopen-2017-000284","article-title":"QTWiST analysis of the RECOURSE trial of trifluridine\/tipiracil in metastatic colorectal cancer","volume":"2","author":"Tabernero","year":"2017","journal-title":"ESMO Open"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2020.06.011_bib51","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1200\/JCO.2018.36.15_suppl.6501","article-title":"Patient-reported outcomes, emoji, and activity measured on the Apple Watch in cancer patients","volume":"36","author":"Thompson","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.011_bib52","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s11136-010-9670-0","article-title":"Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma","volume":"19","author":"Kim","year":"2010","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.011_bib53","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/annonc\/mdt568","article-title":"Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy","volume":"25","author":"Streckmann","year":"2014","journal-title":"Ann Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:13:51Z","timestamp":1760184831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820300745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0889858820300745"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.06.011","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}